1-[7-[5-[(4-fluorophenyl)methyl]-1,3,4-oxadiazol-2-yl]-8-hydroxy-1,6-naphthyridin-5-yl]-3-methylimidazolidin-2-one
C21H17FN6O3 — CID 135869515
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-[7-[5-[(4-fluorophenyl)methyl]-1,3,4-oxadiazol-2-yl]-8-hydroxy-1,6-naphthyridin-5-yl]-3-methylimidazolidin-2-one
1-[7-[5-[(4-fluorophenyl)methyl]-1,3,4-oxadiazol-2-yl]-8-hydroxy-1,6-naphthyridin-5-yl]-3-methylimidazolidin-2-one (PubChem CID 135869515) has the molecular formula C21H17FN6O3 and a molecular weight of 420.40 g/mol. Its IUPAC name is 1-[7-[5-[(4-fluorophenyl)methyl]-1,3,4-oxadiazol-2-yl]-8-hydroxy-1,6-naphthyridin-5-yl]-3-methylimidazolidin-2-one.
Molecular Properties
| Compound Name | 1-[7-[5-[(4-fluorophenyl)methyl]-1,3,4-oxadiazol-2-yl]-8-hydroxy-1,6-naphthyridin-5-yl]-3-methylimidazolidin-2-one |
|---|---|
| PubChem CID | 135869515 |
| Molecular Formula | C21H17FN6O3 |
| Molecular Weight | 420.40 g/mol |
| Exact Mass | 420.13 |
| IUPAC Name | 1-[7-[5-[(4-fluorophenyl)methyl]-1,3,4-oxadiazol-2-yl]-8-hydroxy-1,6-naphthyridin-5-yl]-3-methylimidazolidin-2-one |
| SMILES | CN1CCN(c2nc(-c3nnc(Cc4ccc(F)cc4)o3)c(O)c3ncccc23)C1=O |
| InChI | InChI=1S/C21H17FN6O3/c1-27-9-10-28(21(27)30)19-14-3-2-8-23-16(14)18(29)17(24-19)20-26-25-15(31-20)11-12-4-6-13(22)7-5-12/h2-8,29H,9-11H2,1H3 |
| InChIKey | CYVHFETYRROQFP-UHFFFAOYSA-N |
| XLogP | 2.99 |
| TPSA | 108.48 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 420.40 |
| LogP ≤ 5 | 2.99 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 135869515 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.